- Ingrid Torjesen
- 1London
The European Medicines Agency has committed itself to publishing full clinical trial data submitted by companies for a clinical product once it has recommended granting marketing authorisation for that product.
The commitment will apply only to products that complete the marketing authorisation process from a set date, expected to be 1 January 2014. It will not apply to products granted marketing authorisation before this date.
This means that the agency will not have to make data available on cases of sudden death after a first dose of the multiple sclerosis drug fingolimod or safety data on …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.